Follow up duration of phase III Multiple Myeloma Clinical Trials: A systematic review

Long‐term follow‐up of multiple myeloma (MM) clinical trials are needed to assess long‐term outcomes. We aimed to investigate the length of follow‐up of all phase III MM clinical trials. Median follow‐up duration of clinical trials of newly diagnosed MM was longer when compared to relapsed/refractor...

Descripción completa

Detalles Bibliográficos
Autores principales: Ali, Mohammad O., Abdullah, Hafez M., Obeidat, Khaldun, Chakraborty, Rajshekhar, Al Hadidi, Samer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10435726/
https://www.ncbi.nlm.nih.gov/pubmed/37601879
http://dx.doi.org/10.1002/jha2.680
_version_ 1785092167264370688
author Ali, Mohammad O.
Abdullah, Hafez M.
Obeidat, Khaldun
Chakraborty, Rajshekhar
Al Hadidi, Samer
author_facet Ali, Mohammad O.
Abdullah, Hafez M.
Obeidat, Khaldun
Chakraborty, Rajshekhar
Al Hadidi, Samer
author_sort Ali, Mohammad O.
collection PubMed
description Long‐term follow‐up of multiple myeloma (MM) clinical trials are needed to assess long‐term outcomes. We aimed to investigate the length of follow‐up of all phase III MM clinical trials. Median follow‐up duration of clinical trials of newly diagnosed MM was longer when compared to relapsed/refractory MM clinical trials (42.7 vs. 20.5 months, respectively). The follow‐up duration of phase III clinical trials in MM is relatively short when compared to the improved outcomes in the current era. Efforts should be made to facilitate long‐term clinical trials follow‐up and/or publication of results of updated results.
format Online
Article
Text
id pubmed-10435726
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-104357262023-08-19 Follow up duration of phase III Multiple Myeloma Clinical Trials: A systematic review Ali, Mohammad O. Abdullah, Hafez M. Obeidat, Khaldun Chakraborty, Rajshekhar Al Hadidi, Samer EJHaem Short Reports Long‐term follow‐up of multiple myeloma (MM) clinical trials are needed to assess long‐term outcomes. We aimed to investigate the length of follow‐up of all phase III MM clinical trials. Median follow‐up duration of clinical trials of newly diagnosed MM was longer when compared to relapsed/refractory MM clinical trials (42.7 vs. 20.5 months, respectively). The follow‐up duration of phase III clinical trials in MM is relatively short when compared to the improved outcomes in the current era. Efforts should be made to facilitate long‐term clinical trials follow‐up and/or publication of results of updated results. John Wiley and Sons Inc. 2023-06-29 /pmc/articles/PMC10435726/ /pubmed/37601879 http://dx.doi.org/10.1002/jha2.680 Text en © 2023 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Reports
Ali, Mohammad O.
Abdullah, Hafez M.
Obeidat, Khaldun
Chakraborty, Rajshekhar
Al Hadidi, Samer
Follow up duration of phase III Multiple Myeloma Clinical Trials: A systematic review
title Follow up duration of phase III Multiple Myeloma Clinical Trials: A systematic review
title_full Follow up duration of phase III Multiple Myeloma Clinical Trials: A systematic review
title_fullStr Follow up duration of phase III Multiple Myeloma Clinical Trials: A systematic review
title_full_unstemmed Follow up duration of phase III Multiple Myeloma Clinical Trials: A systematic review
title_short Follow up duration of phase III Multiple Myeloma Clinical Trials: A systematic review
title_sort follow up duration of phase iii multiple myeloma clinical trials: a systematic review
topic Short Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10435726/
https://www.ncbi.nlm.nih.gov/pubmed/37601879
http://dx.doi.org/10.1002/jha2.680
work_keys_str_mv AT alimohammado followupdurationofphaseiiimultiplemyelomaclinicaltrialsasystematicreview
AT abdullahhafezm followupdurationofphaseiiimultiplemyelomaclinicaltrialsasystematicreview
AT obeidatkhaldun followupdurationofphaseiiimultiplemyelomaclinicaltrialsasystematicreview
AT chakrabortyrajshekhar followupdurationofphaseiiimultiplemyelomaclinicaltrialsasystematicreview
AT alhadidisamer followupdurationofphaseiiimultiplemyelomaclinicaltrialsasystematicreview

Ejemplares similares